전형적인 심방조동 절제를 위해 추천된 환자의 냉동 풍선 폐정맥 격리 (PAF CRIOBLAF)
전형적인 심방조동 환자에서 우지협 절제술과 cryoBalloon 폐정맥 분리술을 병용하여 심방세동을 예방
- Background:
Atrial fibrillation is frequently associated with typical atrial flutter in clinical practice. If the radical treatment of atrial flutter by radiofrequency catheter is achieved in most cases without recurrence, it does not prevent the occurrence of atrial fibrillation that occurs in about 70% of these patients after several years of follow-up. However, the latter arrhythmia is associated with significant morbidity and mortality. The problem of atrial fibrillation occurrence after successful ablation of typical atrial flutter remains physicians primary concern in monitoring these patients.
- Objectives:
The purpose of this study is to demonstrate that the pulmonary veins isolation using balloon cryotherapy technology performed at the time of flutter ablation, significantly reduces the risk of developing atrial fibrillation in the two year period following the procedure.
- Selection Criteria:
Patients referred for ablation of typical atrial flutter with an history of at least one documented episode of atrial fibrillation (atrial flutter remaining the predominant arrhythmia)will be enrolled in the study.
- Study Methods:
This is a prospective, multicenter, randomized, 2-arms study, comparing the rate of atrial fibrillation occurrence over a two years period following either an ablation procedure of typical atrial flutter (Group 1), or a combined procedure of typical atrial flutter ablation and pulmonary veins cryoballoon isolation (Group 2). The enrollment period will be of 18 months.
Randomization will be 1:1 and will be balanced in blocks of varying size. Patients will then be regularly followed up clinically and by long-term ECG recordings.
- Evaluation Criteria:
The primary endpoint will be the recurrence of symptomatic or asymptomatic atrial fibrillation, documented by an ECG or an R-test, occurring between M3 and M24
-
Number of patients:
170 patients will be enrolled in the study
-
Number of centers:
Four French and three German centers will participate.
- Perspective:
The demonstration of a clinical benefit in terms of atrial fibrillation risk reduction in the patient group with pulmonary vein isolation, could lead to a modification of atrial arrhythmia treatment indication.
연구 개요
상태
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Brest, 프랑스
- CHU de Brest
-
Grenoble, 프랑스, 38000
- CHU Grenoble
-
La Rochelle, 프랑스
- CH La Rochelle
-
Marseille, 프랑스
- AP-HM - Hôpital Nord
-
Marseille, 프랑스
- Hôpital Privé de Clairval
-
Nantes, 프랑스
- CHU de Nantes
-
Nantes, 프랑스
- Nouvelles Cliniques Nantaises
-
Rennes, 프랑스, 35033
- CHU de Rennes
-
Rouen, 프랑스, 76000
- University Hospital of Rouen
-
Strasbourg, 프랑스
- CHU de Strasbourg
-
Toulouse, 프랑스, 31076
- Clinique Pasteur
-
Tours, 프랑스
- CHU de Tours
-
Tours, 프랑스
- Clinique Saint Gatien
-
Trélazé, 프랑스
- Clinique Saint Joseph
-
Valenciennes, 프랑스
- Polyclinique Vauban
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
-
Inclusion Criteria:
- Patient with a spontaneous flutter or with a flutter recurrence when it was not considered appropriate to use a preventive treatment so far. The flutter may have been paroxysmal or may still be present.
- Patient with at least one documented episode of typical flutter defined as follows: negative F waves in the inferior territory, positive in V1 and negative in V6 lead, F wave pattern with characteristic "saw tooth" appearance and finally a heart rate comprised between 240 and 320 beats per minute.
- Patient with effective anticoagulant therapy for at least 3 weeks.
- Patient with at least one episode of AF (lasting more than 1 minute) documented on an ECG or a 24 hour Holter recording
- Patient who signed an informed consent.
- Patient with age ≥ 18 yo and ≤ 75 yo
-
Exclusion Criteria:
-
Patients with the following characteristics will be excluded:
- Contraindication to right-heart catheterization
- Contraindication to an anticoagulant treatment
- Patient for which AF is predominant (more recordings of AF than Flutter)
- Persistent AF at the time of inclusion visit
- History of mitral valve surgery
- Known disorders of blood clotting
- Cardiothyreosis
-
Life expectancy < 24 months
-
Less than 18 years old and pregnant ladies. As before any ablation, a pregnancy test will be done the day before or the day of the procedure
-
Patient less than 18 years old
-
Patient under guardianship
-
Patient deprived of their liberty by a court decision
-
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Atrial flutter ablation
RF atrial flutter ablation |
Radiofrequency ablation of Atrial flutter |
|
실험적: Atrial flutter ablation and pulmonary vein isolation
RF Atrial flutter ablation and pulmonary vein isolation using cryoablation |
Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recurrence of symptomatic or asymptomatic AF as documented on an ECG or a long term Holter
기간: an average of 24 months following the ablation procedure
|
Main endpoint will be the recurrence of symptomatic or asymptomatic atrial fibrillation as documented by an ECG or a R-test. Sustained AF episodes of more than a minute will be classified depending if they are symptomatic or not. |
an average of 24 months following the ablation procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recurrence rate of typical atrial flutter
기간: an average of 24 months following the ablation procedure
|
Recurrence rate of typical atrial flutter |
an average of 24 months following the ablation procedure
|
|
Rate of occurrence of atypical flutter
기간: an average of 24 months following the ablation procedure
|
Occurrence rate of atypical flutter defined as a continuous atrial activity (with no return to the isoelectric line)in at least one lead, whose ECG appearance of F waves is different from that of a typical flutter |
an average of 24 months following the ablation procedure
|
|
Rate of occurrence of atrial tachycardia
기간: an average of 24 months following the ablation procedure
|
Rate of occurrence of atrial tachycardia defined as an atrial activaty that generates a P wave with return to the isoelectric line in all leads |
an average of 24 months following the ablation procedure
|
|
Rate of complications related to the ablation procedure
기간: an average of 3 months after the ablation procedure
|
The following complications will be considered: Hematoma at punction site, Thromboembolic accident, Tamponnade, Phrenic nerve paralysis, Symptomatic stenosis of pulmonary vein, Atrio-ventricular block Atrioesophageal fistula |
an average of 3 months after the ablation procedure
|
|
Rate of major cardiovascular events
기간: an average of 24 months following the ablation procedure
|
Rate of major cardiovascular events such as rehospitalization for arrhythmia, heart failure, or embolic accident |
an average of 24 months following the ablation procedure
|
|
All mortality rate
기간: an average of 24 months following the ablation procedure
|
All mortality rate (including sudden death and any type of death) |
an average of 24 months following the ablation procedure
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Frederic Anselme, MD, University Hospital, Rouen
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .